References
- Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. Surv Ophthalmol. 2007;52(1):13–31. doi:10.1016/j.survophthal.2006.10.003
- Giordano CN, Matarasso SL, Ozog DM. Injectable and topical neurotoxins in dermatology: indications, adverse events, and controversies. J Am Acad Dermatol. 2017;76(6):1027–1042. doi:10.1016/j.jaad.2016.11.012
- Aesthetic plastic surgery national databank statistics 2019. The Aesthetic Society Web site. Available from: http://www.surgery.org. Accessed November 23, 2020.
- Samizadeh S, De Boulle K. Botulinum neurotoxin formulations: overcoming the confusion. Clin Cosmet Investig Dermatol. 2018;11:273–287. doi:10.2147/CCID.S156851
- Hanna E, Pon K. Updates on botulinum neurotoxins in dermatology. Am J Clin Dermatol. 2020;21(2):157–162. doi:10.1007/s40257-019-00482-2
- Rogozhin AA, Pang KK, Bukharaeva E, Young C, Slater CR. Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A. J Physiol. 2008;586(13):3163–3182. doi:10.1113/jphysiol.2008.153569
- Park JY, Sunga O, Wanitphakdeedecha R, Frevert J. Neurotoxin impurities: a review of threats to efficacy. Plast Reconstr Surg Glob Open. 2020;8(1):e2627. doi:10.1097/GOX.0000000000002627
- Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins. 2019;11:491. doi:10.3390/toxins11090491
- Srinoulprasert Y, Kantaviro W, Nokdhes YN, et al. Development of inhibition ELISA to detect antibody-induced failure of botulinum toxin a therapy in cosmetic indications. J Immunol Methods. 2019;473:112635. doi:10.1016/j.jim.2019.112635
- Albrecht P, Jansen A, Lee JI, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019;92(1):e48–e54. doi:10.1212/WNL.0000000000006688
- Wanitphakdeedecha R, Kantaviro W, Suphatsathienkul P, et al. Association between secondary botulinum toxin a treatment failure in cosmetic indication and anti-complexing protein antibody production. Dermatol Ther. 2020;10(4):707–720. doi:10.1007/s13555-020-00397-5
- Lacroix-Desmazes S, Mouly S, Popoff MR, Colosimo C. Systematic analysis of botulinum neurotoxin type A immunogenicity in clinical studies. Basal Ganglia. 2017;9:12–17. doi:10.1016/j.baga.2017.06.001
- Field M, Splevins A, Picaut P, et al. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins. 2018;10(12):535. doi:10.3390/toxins10120535
- Dressler D, Pan L, Adib Saberi F. Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity. J Neural Transm. 2018;125(10):1481–1486. doi:10.1007/s00702-018-1911-3
- Fabbri M, Leodori G, Fernandes RM, et al. Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis. Neurotox Res. 2016;29(1):105–117. doi:10.1007/s12640-015-9565-5
- Dressler D, Bigalke H. Reconstituting botulinum toxin drugs: shaking, stirring or what? J Neural Transm. 2016;123(5):523–525. doi:10.1007/s00702-016-1538-1